Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study

被引：0
|
作者：
Moore, Kathleen N.
Sabanathan, Dhanusha
Du, Yiqun
Duan, Huaxin
Li, Xiumin
Wang, Feng
Marathe, Omkar
Yang, Hua
Makker, Vicky
Growdon, Whitfield
Coward, Jim
Zhao, Peng
Liu, Liming
Shi, Rong
Liu, Shengxue
Gu, Wei
Qiu, Yang
Zhu, Zhongyuan
Zhang, Jian
Hamilton, Erika P.
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Macquarie Univ, Canc Inst, Sydney, Australia
[3] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[4] Hunan Prov Peoples Hosp, Changsha, Peoples R China
[5] Linyi Canc Hosp, Shandong, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Inst Oncol, Lakewood, CA USA
[8] Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med Coll, New York, NY USA
[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[12] ICON Canc Ctr, Brisbane, Australia
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Dual Biol, Philadelphia, PA USA
[15] Dual Biol, Princeton, NJ USA
[16] Dual Biol, Shanghai, Peoples R China
[17] Dual Biol, Basking Ridge, NJ USA
[18] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[19] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[20] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3023
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [32] A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Van Tine, Brian Andrew
    McLeod, Robert
    Laadem, Abderrahmane
    Cheng, Ben
    Nishioka, Satoshi
    Kundu, Madan Gopal
    Qian, Xiaozhong
    Lau, Yvonne Y.
    Tran, Brittany
    Kumar, Prasanna
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09) : 1133 - 1142
  • [34] A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors
    McKean, Meredith
    Powderly, John D.
    Duncan, Meghan
    Norman, Teleen
    Patel, Ekta
    O'Neil, Jennifer
    Lee, George
    Luptakova, Katarina
    Kaufman, Howard E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
    Zhang, Jun
    Chavez, Jorge
    Chan, Nancy
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E27 - E27
  • [36] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
    Patel, Manish R.
    Falchook, Gerald Steven
    Wang, Judy Sing-Zan
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Motlagh, Pejvack
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne Fields
    Spigel, David R.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors
    Richardson, Gary Edward
    Al-Rajabi, Raed
    Uprety, Dipesh
    Hamid, Anis
    Williamson, Stephen K.
    Baranda, Joaquina
    Mamdani, Hirva
    Lee, Ya-Li
    Li, Li
    Wang, Xingli
    Dong, Xunwei
    CANCERS, 2023, 15 (09)
  • [38] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
    Bechter, Oliver
    Loquai, Carmen
    Champiat, Stephane
    Baurain, Jean Francois
    Grob, Jean-Jacques
    Utikal, Jochen
    Rottey, Sylvie
    Berrocal, Alfonso
    Hassel, Jessica
    Arance, Ana
    Sanmamed, Miguel F.
    Boers-Sonderen, Marye
    Gastman, Brian
    Gebhardt, Christoffer
    Delafontaine, Brant
    Sahin, Ugur
    Tureci, Ozlem
    Abbadessa, Giovanni
    Di Genova, Gianfranco
    Brueck, Patrick
    Marpadga, Rahul
    Lee, Helen
    Lebbe, Celeste
    CANCER RESEARCH, 2023, 83 (08)
  • [40] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
12345